GGrantIndex
← Leaderboards

Xinping Yue

Tulane University Of Louisiana

$1,333,173
Attributed
$2,906,519
Total exposure
3
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $717.5K · FY200921
$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$2,906,519 · 3

By mechanism

R01$2,360,019 · 1
R21$397,500 · 1
R03$149,000 · 1

Top collaborators

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Lung

Research focus

LungLeadCell TypePathogenesisOrganOverexpressionImpairmentPlayTissuesSignal TransductionPulmonary FibrosisMolecularFibrosisKnock-OutPulmonary FunctionCleaved CellCongestive Heart FailureAntihypertensive AgentsAldosteroneChronicCoronary FibrosisCardiopulmonaryCardiovascular DiseasesAngiotensin Ii Receptor

Grant awards (11)

Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$396,097
R01 · FY2021 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$404,754
R01 · FY2020 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$312,700
R01 · FY2020 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$413,160
R01 · FY2019 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$421,318
R01 · FY2018 · HL
Chronic nicotine inhalation increases susceptibility to cardiovascular and pulmonary diseases through inhibition of local compensatory mechanisms$411,990
R01 · FY2017 · HL
Role of Heparan Sulfate 6-O-Endosulfatase 1 and 2 in Pulmonary Fibrosis$174,507
R21 · FY2011 · HL · contact PI
Role of Heparan Sulfate 6-O-Endosulfatase 1 and 2 in Pulmonary Fibrosis$11,743
R21 · FY2011 · HL · contact PI
Role of Heparan Sulfate 6-O-Endosulfatase 1 and 2 in Pulmonary Fibrosis$211,250
R21 · FY2010 · HL · contact PI
Expression of Heparan Sulfate 6-O-Endosulfatases in Idiopathic Pulmonary Fibrosis$74,500
R03 · FY2010 · HL · contact PI
Expression of Heparan Sulfate 6-O-Endosulfatases in Idiopathic Pulmonary Fibrosis$74,500
R03 · FY2009 · HL · contact PI